Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 44

1.

Combination of BRAF Inhibitors and Brain Radiotherapy in Patients With Metastatic Melanoma Shows Minimal Acute Toxicity.

Rompoti N, Schilling B, Livingstone E, Griewank K, Hillen U, Sauerwein W, Pöttgen C, Stuschke M, Schadendorf D, Zimmer L.

J Clin Oncol. 2013 Oct 20;31(30):3844-5. doi: 10.1200/JCO.2013.50.8473. No abstract available.

PMID:
24062392
2.

Reply to N. Rompoti et al.

Satzger I, Degen A, Asper H, Kapp A, Hauschild A, Gutzmer R.

J Clin Oncol. 2013 Oct 20;31(30):3845-6. doi: 10.1200/JCO.2013.51.8936. No abstract available.

PMID:
24062398
3.

Serious skin toxicity with the combination of BRAF inhibitors and radiotherapy.

Satzger I, Degen A, Asper H, Kapp A, Hauschild A, Gutzmer R.

J Clin Oncol. 2013 May 1;31(13):e220-2. doi: 10.1200/JCO.2012.44.4265. No abstract available.

PMID:
23530102
4.

Radiosensitization by BRAF inhibitor therapy-mechanism and frequency of toxicity in melanoma patients.

Hecht M, Zimmer L, Loquai C, Weishaupt C, Gutzmer R, Schuster B, Gleisner S, Schulze B, Goldinger SM, Berking C, Forschner A, Clemens P, Grabenbauer G, Müller-Brenne T, Bauch J, Eich HT, Grabbe S, Schadendorf D, Schuler G, Keikavoussi P, Semrau S, Fietkau R, Distel LV, Heinzerling L.

Ann Oncol. 2015 Jun;26(6):1238-44. doi: 10.1093/annonc/mdv139.

PMID:
25762352
5.

Nephrotoxicity of the BRAF Inhibitors Vemurafenib and Dabrafenib.

Jhaveri KD, Sakhiya V, Fishbane S.

JAMA Oncol. 2015 Nov;1(8):1133-4. doi: 10.1001/jamaoncol.2015.1713.

PMID:
26182194
6.

Panniculitis in patients treated with BRAF inhibitors: a case series.

Choy B, Chou S, Anforth R, Fernández-Peñas P.

Am J Dermatopathol. 2014 Jun;36(6):493-7. doi: 10.1097/DAD.0000000000000023.

PMID:
24879511
7.

[New treatment options for metastatic melanoma].

Tietze JK, Berking C.

Dtsch Med Wochenschr. 2014 Jul;139(28-29):1462-7. doi: 10.1055/s-0034-1370155. Review. German. No abstract available.

PMID:
24983194
8.

Treatment of BRAF inhibitor-induced hyperkeratosis.

Battley JE, Lenihan E, Redmond HP, Murphy M, Power DG.

Acta Oncol. 2013 May;52(4):874-7. doi: 10.3109/0284186X.2012.716165. No abstract available.

PMID:
22998476
9.

Oral squamous cell carcinoma and hyperkeratotic lesions with BRAF inhibitors.

Vigarios E, Lamant L, Delord JP, Fricain JC, Chevreau C, Barrés B, Gomez-Roca C, Boulanger M, Sibaud V.

Br J Dermatol. 2015 Jun;172(6):1680-2. doi: 10.1111/bjd.13610. No abstract available.

PMID:
25495246
10.

Second primary melanomas on treatment with vemurafenib.

Dalle S, Poulalhon N, Debarbieux S, Thomas L.

Br J Dermatol. 2013 Apr;168(4):887-8. doi: 10.1111/bjd.12093. No abstract available.

PMID:
23066856
11.

BRAF Inhibitor-Induced Panniculitis: Appearance on 18F-FDG PET/CT.

Broski SM, Moran EK, Glazebrook KN, Nathan MA.

Clin Nucl Med. 2016 Mar;41(3):e149-51. doi: 10.1097/RLU.0000000000001027.

PMID:
26447389
12.

Topical 5-fluorouracil elicits regressions of BRAF inhibitor-induced cutaneous squamous cell carcinoma.

Viros A, Hayward R, Martin M, Yashar S, Yu CC, Sanchez-Laorden B, Zambon A, Niculescu-Duvaz D, Springer C, Lo RS, Marais R.

J Invest Dermatol. 2013 Jan;133(1):274-6. doi: 10.1038/jid.2012.268. No abstract available. Erratum in: J Invest Dermatol. 2013 Jun;133(6):1691.

13.

Vemurafenib-induced toxic epidermal necrolysis: possible cross-reactivity with other sulfonamide compounds.

Bellón T, Lerma V, González-Valle O, González Herrada C, de Abajo FJ.

Br J Dermatol. 2016 Mar;174(3):621-4. doi: 10.1111/bjd.14201.

PMID:
26412570
14.

Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors.

Amaravadi RK, Hamilton KE, Ma X, Piao S, Portillo AD, Nathanson KL, Carlino MS, Long GV, Puzanov I, Xu X, Morrissette JJ, Tsai KY, Flaherty KT, Sosman JA, Goodman GR, McArthur GA, Rustgi AK, Metz DC, Schuchter LM, Chapman PB, Sepulveda AR.

Clin Cancer Res. 2015 Dec 1;21(23):5215-21. doi: 10.1158/1078-0432.CCR-15-0469.

15.

Vemurafenib-induced radiation recall dermatitis: case report and review of the literature.

Conen K, Mosna-Firlejczyk K, Rochlitz C, Wicki A, Itin P, Arnold AW, Gross M, Zimmermann F, Zippelius A.

Dermatology. 2015;230(1):1-4. doi: 10.1159/000365918. Review.

PMID:
25472806
16.

[BRAF: the pathologist's favorite oncogene].

Sabourin JC.

Ann Pathol. 2013 Dec;33(6):373-4. doi: 10.1016/j.annpat.2013.11.001. French. No abstract available.

PMID:
24331718
17.

The wrath of RAFs: rogue behavior of B-RAF kinase inhibitors.

Kaplan FM, Mastrangelo MJ, Aplin AE.

J Invest Dermatol. 2010 Nov;130(11):2669-71. doi: 10.1038/jid.2010.177. No abstract available.

18.

Second primary melanomas on treatment with vemurafenib: reply from the authors.

Fearfield L, Newton-Bishop JA, Sinha R, Edmonds K, Gore ME, Larkin J.

Br J Dermatol. 2013 Apr;168(4):888-9. doi: 10.1111/bjd.12094. No abstract available.

PMID:
23066884
19.

Haemorrhage due to proteolysis of FXIII and hyperfibrinolysis under vemurafenib treatment of metastatic melanoma.

Trappe R, Budde U, Zimmermann H.

Thromb Haemost. 2012 Oct;108(4):798-800. No abstract available.

PMID:
22918265
20.

BRAF inhibitor activity in V600R metastatic melanoma--response.

Klein O, Clements A, Menzies AM, O'Toole S, Kefford RF, Long GV.

Eur J Cancer. 2013 May;49(7):1797-8. doi: 10.1016/j.ejca.2013.02.010. No abstract available.

PMID:
23490649
Items per page

Supplemental Content

Support Center